Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alkaline phosphatase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44363   clinical trials with a EudraCT protocol, of which   7387   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,556 result(s) found for: Alkaline phosphatase. Displaying page 1 of 78.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-004826-12 Sponsor Protocol Number: MAP4B-safety Start Date*: 2021-07-27
    Sponsor Name:Association of Dutch Burn Centres
    Full Title: Safety and preliminary efficacy of Alkaline Phosphatase in severely burned patients
    Medical condition: Severe Burns
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002663-33 Sponsor Protocol Number: NUH-ALS-2015-04 Start Date*: 2018-11-05
    Sponsor Name:Alloksys Life Sciences BV
    Full Title: Preventing Oxidative stress induced Ischemic Injury and Systemic Inflammation complications during and after invasive Cardiac surgery with Alkaline Phosphatase (APPIRED III)
    Medical condition: systemic inflammation as side-effect of heart-lung machine during cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004863 10017501 Functional disturbances following cardiac surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) NL (Completed) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004737-85 Sponsor Protocol Number: 1.3 Start Date*: 2018-12-11
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Alkaline Phosphatase to prevent ischemia reperfusion injury in living kidney transplantation
    Medical condition: Ischemia reperfusion injury in living donor kidney transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-024013-31 Sponsor Protocol Number: CBPS804A2202 Start Date*: 2011-06-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, intra-patient dose-escalation study to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of multiple infusions of BPS804 in adults wit...
    Medical condition: Hypophosphatasia (HPP) is a rare genetic metabolic disorder which results in impaired skeletal mineralization, and which is caused by the absence of or by deficient enzymatic activity of the tissue...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002276-17 Sponsor Protocol Number: ET-B-025-02 Start Date*: 2006-08-24
    Sponsor Name:Pharma Mar SA, Sociedad Unipersonal
    Full Title: Phase II Study of Yondelis® in Men with Advanced Prostate Carcinoma Estudio fase II con Yondelis en hombres con cáncer de próstata avanzado
    Medical condition: Advanced Prostate Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    7.1 10036909 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-006767-14 Sponsor Protocol Number: NL79196.018.21 Start Date*: 2022-08-24
    Sponsor Name:Amsterdam UMC
    Full Title: Alkaline Phosphatase as treatment of Ischemia Reperfusion Injury to prevent delayed graft function
    Medical condition: ischemia reperfusion injury in kidneys transplanted from donors after cardiac death
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002505-10 Sponsor Protocol Number: NL77754.018.21 Start Date*: 2021-11-30
    Sponsor Name:Amsterdam University Medical Centre
    Full Title: Rescue Alkaline Phosphatase In Defense against all cause Acute Kidney Injury (RAPID-AKI)
    Medical condition: Acute kidney injury
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    20.1 10038359 - Renal and urinary disorders 10080269 Stage 2 acute kidney injury LLT
    20.1 10038359 - Renal and urinary disorders 10080271 Stage 3 acute kidney injury LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000769-13 Sponsor Protocol Number: AP SEP 02-02 Start Date*: 2006-06-13
    Sponsor Name:AM-Pharma
    Full Title: A double-blind, randomized, placebo-controlled study to investigate the clinical efficacy and safety of two doses of Alkaline Phosphatase administered for three days in patients with severe sepsi...
    Medical condition: Severe sepsis and septic shock
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-007406-11 Sponsor Protocol Number: ENB-002-08 Start Date*: 2009-02-25
    Sponsor Name:Enobia Canada Limited Partnership
    Full Title: A Multicenter, Open-Label Study of the Safety, Tolerability and Pharmacology of ENB-0040 (Enobia’s human recombinant tissue non-specific alkaline phosphatase fusion protein) in up to 6 Severely Aff...
    Medical condition: Infantile Hypophosphatasia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003153-42 Sponsor Protocol Number: ENB-008-10 Start Date*: 2017-08-03
    Sponsor Name:Alexion Pharma GmbH
    Full Title: Extension Study of Protocol ENB-006-09 Evaluating the Long-Term Safety and Efficacy of Asfotase Alfa (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Children with Hyp...
    Medical condition: Hypophosphatasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-001128-52 Sponsor Protocol Number: ENB-006-09 Start Date*: 2015-05-28
    Sponsor Name:Alexion Pharma International Sàrl
    Full Title: A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Historical Control Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ENB-0040 (Human Recombinant Tissue-No...
    Medical condition: Hypophosphatasia (HPP)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019850-42 Sponsor Protocol Number: ENB-010-10 Start Date*: 2011-03-04
    Sponsor Name:Alexion Pharma GmbH
    Full Title: An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase alfa (human recombinant tissue nonspecific alkaline phosphatase fusion protein) in Infants a...
    Medical condition: Hypophosphatasia is a rare inborn error of bone metabolism caused by inactivating mutations in the gene encoding the Tissue-nonspecific alkaline phosphatase isoenzyme. With deficiency of Tissue-...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed) ES (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-001957-16 Sponsor Protocol Number: BREAST-SK-001 Start Date*: 2019-10-31
    Sponsor Name:Národný onkologický ústav
    Full Title: Phase II study of Vinorelbine, cisplatin, disulfiram and copper in CTC_EMT positive refractory metastatic breast cancer.
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SK (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-004570-34 Sponsor Protocol Number: 01045-ATLEP Start Date*: 2018-11-15
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Phase II, Open-label, Study in Patients with anaplastic (ATC) or poorly differentiated thyroid carcinomas (PDTC) to investigate the Clinical Efficacy and Safety of the Combination Therapy of Lenvat...
    Medical condition: Anaplastic (ATC) or Poorly Differentiated Thyroid Carcinoma (PDTC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076603 Poorly differentiated thyroid carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002240 Anaplastic thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000761-40 Sponsor Protocol Number: AP-recAP-AKI-02-01 Start Date*: 2014-10-22
    Sponsor Name:AM-Pharma B.V.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Parallel-Group, Proof of Concept, and Dose-Finding Adaptive Phase 2a/2b Study to Investigate the Safety, Tolerability and Efficacy and Effe...
    Medical condition: Sepsis-Associated Acute Kidney Injury
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) CZ (Completed) AT (Completed) NL (Completed) ES (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001831-38 Sponsor Protocol Number: ENB-009-10 Start Date*: 2017-05-09
    Sponsor Name:Alexion Pharma GmbH
    Full Title: A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control Study of the Safety, Efficacy, and Pharmacokinetics of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline...
    Medical condition: Hypophosphatasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000809-39 Sponsor Protocol Number: AA-HPP-405 Start Date*: 2016-02-04
    Sponsor Name:Alexion Pharma International Sàrl
    Full Title: An Open-label, Multicenter, Expanded Access Program for Asfotase Alfa (human recombinant tissue-nonspecific alkaline phosphatase fusion protein) Treatment for Patients with Infantile- or Juvenile-o...
    Medical condition: Hypophosphatasia
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-007346-63 Sponsor Protocol Number: ALS-003-2008 Start Date*: 2011-04-05
    Sponsor Name:Alloksys Life Sciences B.V.
    Full Title: Reumap: An Open Label phase II study of Bovine Intestinal Alkaline Phosphatase (bIAP), An Inflammation modulating moiety, in RA patients
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2009-009369-32 Sponsor Protocol Number: ENB-003-08 Start Date*: 2009-03-30
    Sponsor Name:Alexion Pharma GmbH
    Full Title: Extension Study of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Severely Affected Infants and Young Children with Hypophosphatasia (HPP)
    Medical condition: Infantile hypoposphatasia
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10049933 Hypophosphatasia PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-000321-41 Sponsor Protocol Number: ALENDROHNP2011 Start Date*: 2012-04-18
    Sponsor Name:FUNDACION HOSPITAL NACIONAL DE PARAPLEJICOS PARA LA INVESTIGACIÓN Y LA INTEGRACIÓN
    Full Title: PREVENTIVE TREATMENT OF BONE MASS LOSS WITH ALENDRONATE AND CALCIFEDIOL IN PATIENTS WITH ACUTE SPINAL CORD INJURY
    Medical condition: Preventing loss of bone density in patients with spinal cord injury of traumatic etiology complete during the first year of evolution of the lesion.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10041543 Spinal cord and nerve root disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Nov 05 14:21:26 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA